Menopausal Hot Flashes Market Size, Share & Industry Analysis, By Treatment Type (Hormonal Treatment {Estrogen, Progesterone, Estrogen-progesterone Combination},Non-hormonal Treatment, {Antidepressants, Others}, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2024-2032

Hot flashes are one of the most common symptoms experienced by women around the world during the transition to and through menopause. The prevalence rates tend to be higher in western countries than in asian countries but sometimes the rates vary widely and are influenced by various factors. Growing population of elderly women with rise in menopausal hot flash symptoms, increase in awareness about women’s health by various public and private organisations initiatives, and various number of treatment launches by key market players are some of the factors that are expected to drive the market growth during the forecast period. For instance, according to an article published by National Center for Biotechnology Information (NCBI), it is estimated that about 1.2 billion women worldwide will be menopausal or post-menopausal by the year 2030.

The overall menopausal hot flashes market is expected to witness significant growth during the forecast period due to factors such as growing population of elderly women with rise in menopausal hot flash symptoms, increase in awareness about women’s health by various public and private organizations initiatives. However, side effects associated with hormonal products is anticipated to restrict the menopausal hot flashes market.

Market Segmentation:

Globally, the menopausal hot flashes market can be segmented on the bases of the treatment type, distribution channels, and region. Based on the treatment type the market can be segmented into hormonal treatment, non-hormonal treatment, and others. Based on the hormonal treatment, the market can be further segmented into estrogen, progesterone, and estrogen-progesterone combination. Based on non-hormonal treatment, the market can be further segmented into antidepressants and others. Based on the distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Geographically, the menopausal hot flashes market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the menopausal hot flashes market are Pfizer Inc., Allergan, Teva Pharmaceutical Industries Ltd., Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., GlaxoSmithKline plc, Novo Nordisk A/S, and other prominent players.

Key Insights:

• Pricing Analysis by Key Companies


• Prevalence of menopausal hot flashes by country/region


• New Product Launches


• Key Industry Developments Mergers, Acquisitions, And Collaborations

Regional Analysis:

Geographically, the menopausal hot flashes market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is likely to dominate the menopausal hot flashes market owing to the rising women geriatric population with menopausal symptoms. In U.S., hot flashes are one of the main reasons women at menopause seek medical help. For instance, according to article published by National Center for Biotechnology Information (NCBI), it is estimated that about 85% of post-menopausal women have experienced a menopause-related symptom (hot flashes). Europe is projected to hold second largest market share throughout the forecast period. The development of new products and partnership activities of major market players is likely to boost the growth of the menopausal hot flashes market in this region. Along with this, the rising women geriatric population also drives the growth of market in this region. However, Asia Pacific is expected to grow with the highest CAGR due to an increasing prevalence of menopausal symptoms in women.

On the other hand, the market in Latin America and the Middle East & Africa is anticipated to have a substantial market growth during the forecast period owing to the rising patient demand for menopausal hot flashes medications due to increasing prevalence of these symptoms and growing governmental and non-governmental initiatives for improving the women healthcare.

Segmentation

Menopausal Hot Flashes Market Industry Developments

• In April 2019, TherapeuticsMD, Inc. announced the launch of Bijuva (estradiol and progesterone) capsules for the treatment of moderate to severe hot flashes in menopause


• In October 2017, Otsuka Pharmaceutical Co., Ltd., announced the launch of EQUELLE, a dietary supplement for the treatment of hot flashes during menopause